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Background: Small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs are non-coding RNAs involved in
the maturation of other RNA molecules. Alterations of sno/scaRNA expression may play a role in cancerogenesis.
This study elucidates the patterns of sno/scaRNA expression in 211 chronic lymphocytic leukemia (CLL) patients
(Binet stage A) also in comparison with those of different normal B-cell subsets.
Methods: The patterns of sno/scaRNA expression in highly purified CD19+ B-cells of 211 CLL patients and in 18
normal B-cell samples - 6 from peripheral blood, and 12 from tonsils (4 germinal center, 2 marginal zone, 3
switched memory and 3 naïve B-cells) - were analyzed on the Affymetrix GeneChip® Human Gene 1.0 ST array.
Results: CLLs display a sno/scaRNAs expression profile similar to normal memory, naïve and marginal-zone B-cells,
with the exception of a few down-regulated transcripts (SNORA31, -6, -62, and -71C). Our analyses also suggest
some heterogeneity in the pattern of sno/scaRNAs expression which is apparently unrelated to the major biological
(ZAP-70 and CD38), molecular (IGHV mutation) and cytogenetic markers. Moreover, we found that SNORA70F was
significantly down-regulated in poor prognostic subgroups and this phenomenon was associated with the
down-regulation of its host gene COBLL1. Finally, we generated an independent model based on SNORA74A and
SNORD116-18 expression, which appears to distinguish two different prognostic CLL groups.
Conclusions: These data extend the view of sno/scaRNAs deregulation in cancer and may contribute to discover
novel biomarkers associated with the disease and potentially useful to predict the clinical outcome of early stage
CLL patients.Background
Chronic lymphocytic leukemia (CLL) is a clinically hetero-
geneous disease. Some patients have an indolent course
and may survive for years without treatment, while others
have an aggressive and rapidly progressive course [1,2]. Al-
though the current Rai [3] and Binet [4] staging systems
identify patients with high-risk disease, they do not pro-
spectively distinguish patients with potentially evolving
disease from those destined to remain stable for decades.* Correspondence: antonino.neri@unimi.it
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reproduction in any medium, provided the orA number of cellular and molecular markers help to
classify CLL into biologically and clinically distinct sub-
groups, and to predict the clinical course of the disease at
diagnosis [5]. CLL patients with unmutated (UM-CLL)
immunoglobulin heavy chain variable (IGHV) region
genes (>98% homology to germline sequences), increased
expression of the CD38 cell surface antigen, or of the 70-
kd zeta-chain T-cell receptor–associated protein kinase
(ZAP-70) experience a shorter therapy-free interval, a
more aggressive clinical course, and a shorter survival
[6-8]. Specific recurrent chromosomal abnormalities, trad-
itionally detected by Fluorescence in situ Hybridization
(FISH), such as deletions at 13q14 (del13), 11q23 (del11),
17p13 (del17), and trisomy 12 (12+) may also representral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and survival [9-13].
In recent years, the discovery of non-coding RNAs
(ncRNAs) has provided new tools for the understanding
of cancer biology [14]. ncRNAs are functional transcripts
that do not code for proteins, but indeed play a major role
in regulating gene expression at virtually all levels. Among
these, small nucleolar RNAs (snoRNAs) are molecules of
60–300 nucleotides in length that function as guide RNAs
for the post-transcriptional methylation and/or pseu-
douridylation of ribosomal RNAs. Unlike snoRNAs, small
Cajal body-specific RNAs (scaRNAs) accumulate within
the Cajal bodies (i.e. conserved subnuclear organelles that
are present in the nucleoplasm) and can guide both post-
transcriptional modifications of small nuclear RNAs. sno/
scaRNAs can also target other RNAs including mRNAs.
However, a subgroup of so-called “orphan” sno/scaRNAs
exists whose function remain to be clarified. Notably, in
vertebrates most sno/scaRNAs reside in the introns of
protein-coding host genes and are processed out of the ex-
cised introns [15].
Experimental evidence has recently shown that sno/
scaRNAs dysfunction may have a role in the origin of
human cancers [16]. Limited data concerning the in-
volvement of sno/scaRNAs in hematological malignan-
cies have been reported only very recently by us and
others [17-22], and are lacking in CLL.
In the present study, we investigated the sno/scaRNA ex-
pression profiling in a large and representative prospective
series of Binet stage A CLL patients. In addition, we evalu-
ated sno/scaRNAs expression in comparison to that ob-
served in various sub-populations of normal B-cells from
tonsils and peripheral blood B-lymphocytes. Finally, the
sno/scaRNA expression pattern was correlated with clin-




Two hundred and eleven newly diagnosed CLL patients
were prospectively enrolled from several Italian Institutions
in an observational multicenter study (O-CLL1 protocol,
clinical trial.gov identifier NCT00917540) from January
2007 to May 2011. The National Cancer Institute (NCI)-
sponsored Working Group guidelines were followed for
diagnosis and staging [23]. All patients had an absolute
lymphocyte count (ALC) greater than 5000×109/L in the
peripheral blood. Exclusion criteria were the following: i) a
CLL diagnosis exceeding 12 months before registration; ii)
a leukemic phase of lymphoproliferative disorders of B ori-
gin, CD5- and/or CD23- according to flow cytometry ana-
lysis; iii) a clinical Binet stage B or C; iv) need of therapy
according to NCI guidelines and v) age > 70 years. The me-
dian follow-up of this series was 30 months. Diagnosis wasconfirmed by the biological review committee according to
flow cytometry analysis centralized at the National Cancer
Institute (IST) Laboratory in Genoa. Written informed
consent was obtained from all patients in accordance with
the declaration of Helsinki and the study was approved
by the local Ethics Review Committee (Comitato Etico
Provinciale, Modena, Italy).
Peripheral blood mononuclear cells from CLL pa-
tients and normal control, and B-cell sub-populations
from tonsils (i.e. naïve B-cells (N), marginal zone (MZ)-
like, germinal center (GC) and switched memory (SM)
B-cells) were obtained as described in Additional file 1
and Additional file 2.
Biological and molecular analyses were performed in
highly enriched CD19+ B-cells as previously described
[24,25]. CD38 and ZAP-70 expressions were investigated
using a cut-off of 20% and 30% respectively to discriminate
positive from negative patients. Del11, del13, del17, and
12+, IGHV mutation status and stereotyped BCR subtypes
were determined as previously described [26-28]. Specific-
ally, IGHV sequences from 210 patients were submitted to
IMGT V-QUEST analysis software, and were classified as
mutated (M-CLL) or UM-CLL using a discriminating mu-
tation cut-off percentage at 2%.
Gene expression profiling (GEP)
Total RNA from purified CD19+ B-cells of 211 CLL cases
and 18 normal B-cell samples - 6 from peripheral blood,
and 12 from tonsils (4 germinal center, 2 marginal zone, 3
switched memory and 3 naïve B-cells) - were analyzed on
the GeneChip® Human Gene 1.0 ST array (Affymetrix Inc.,
Santa Clara, CA). The raw intensity expression values
were processed by Robust Multi-array Average (RMA)
procedure [29] with the re-annotated Chip Definition Files
(CDF) from BrainArray libraries version 15.0.0 [30] avail-
able at http://brainarray.mbni.med.umich.edu. This cus-
tom CDF reorganized probe sets based on i) more
stringent gene/transcript definitions from UniGene data-
base, and ii) alignment analyses performed on each single
probe included in the probeset [30]. The updated annota-
tions provided a better precision and accuracy in tran-
script expression level estimates compared to the original
Affymetrix definitions [19,31].
Supervised analyses were carried out using the Signifi-
cant Analysis of Microarrays software version 4.00 (SAM;
excel front-end publicly available at http://www-stat.stan-
ford.edu/~tibs/SAM/index.html) [32]. The cutoff point for
statistical significance (at a q-value 0) was determined by
tuning the Δ parameter on the false discovery rate and
controlling the q-value of the selected probes. Hierarchical
agglomerative clustering of the most significant probesets
found was performed adopting Pearson and average as
distance and linkage methods, respectively. DNA-Chip
Analyzer software (dChip) [33] was used to perform
Table 1 Characteristics of CLL patients cohort
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been deposited in the NCBI Gene Expression Omnibus
database (GEO; http://www.ncbi.nlm.nih.gov/geo/) under
accession #GSE46261.
In order to explore the distribution of CLL samples we
applied principal component analysis (PCA) on sno/
scaRNA microarray expression data. PCA was performed
by means of the princomp function in R software, by scal-
ing data and using the associated correlation matrix. Hence
we used the 3dplot to visualize samples by the first three
principal components.
Statistical analysis
We used the Cox proportional hazards model in the
globaltest function of R software (with 100,000 permuta-
tion) to test the association (positive or negative) between
sno/scaRNA expression levels, assumed as continuous
variables and progression free survival (PFS) as clinical
outcome. The list of significant associated sno/scaRNA to
the PFS was reduced to derive a smaller prognostic sno/
scaRNA signature by employing single sno/scaRNA ex-
pression profile. Unsupervised K-means clustering was ap-
plied to each sno/scaRNA to define a threshold splitting
samples with higher expression from those with lower ex-
pression (Additional file 3), in order to test their different
clinical outcome. The survival distributions of patient
groups identified by this approach were tested using the
Kaplan-Meier estimator and log-rank test, and P-values
were calculated according to the standard normal asymp-
totic distribution (survdiff function of the survival R pack-
age). The Benjamini-Hochberg correction has been
applied to consider the false discovery rate that incurred
in the multiple testing. Independence between commonly
used CLL prognostic factors (IGHV mutational status,
ZAP-70, CD38 and unfavorable chromosome aberrations,
namely del11, del17 and 12+) and sno/scaRNAs signature
was assessed using multivariate Cox proportional-hazards
regression procedure by the coxph function in the survival
R package. The robustness of the 2-snoRNA model was
tested using the linear discriminant analysis for the classi-
fication of multivariate observations, with leave-one-out
procedure, using ldafunction in MASS R package. Other
statistical procedures were applied using standard func-
tions in base R package (Kendall Tau correlations and
Wilcoxon rank-sum tests).
Results
Characteristics of CLL patients
Two hundred eleven CLL patients at Binet stage A were
included in the study; most of them were Rai 0 stage
(74.4%). The median follow-up was 30 months (range 1–
65 months). CLL cell samples were characterized for
IGHV somatic mutations, ZAP-70 and CD38 expression
and the presence of typical chromosomal aberrations(del13, del11, del17, and 12+) detected by FISH analysis.
Table 1 summarizes the features of CLL samples.
sno/scaRNA expression profile of CLL cells compared to
normal B-cell populations
The expression profiles of sno/scaRNA genes were
investigated using Human Gene 1.0 ST arrays. Oligo-
nucleotide probes were mapped according to the gen-
ome and transcriptome information from the human
genome build release GRCh37/hg19 (see Methods)
identifying 215 human snoRNA (76 SNORA and 139
SNORD transcripts) and 17 human scaRNA genes. The
expression patterns also were studied in normal B-cells
from peripheral blood (pBC) and in different tonsil
B-cell sub-populations including germinal center (GC),
naïve (N), marginal zone (MZ) and memory (SM) B-
cells (Additional file 2 reports the FACS sorting strategy
used to purify these cell subpopulations as described in
Additional file 1).
At first, we applied PCA on the sno/scaRNA dataset
composed by 211 CLL and 18 normal cell samples; the
first three PCs contained 51% of variance in our data
and we used them to display all the cell type samples in
a three-dimensional plot. As shown in Figure 1A, we ob-
served that CLL, N, MZ and SM B-cell samples were
clustered together, whereas GC and in particular pBC
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PC3 and PC1 components, respectively. Based on this
evidence, multiclass analysis was performed comparing
CLLs with N, MZ and SM (taken as a single group) and
GC B-cells. Despite the heterogeneity of snoRNAs expres-
sion in CLL samples, we confirmed that the sno/scaRNA
expression profile of CLL was much more similar to N-
MZ-SM B-cells rather than to GC (Figure 1A-B). Spe-
cifically, we observed the significant down-regulation of
SNORA31, -6, -62, and 71C, SNORD37, and -50B in CLL
with respect to tonsillar B-cells; however, GC B-cells differed
from both CLL and N-MZ-SM B-cells on the basis of a
number of down-regulated transcripts, such as SNORD116-
1, -116-23, -116-29, -94, and SNORA36A (Figure 1B).
Notably, SNORA31, -6, -62, and -71C also resulted sig-
nificantly down-regulated in each of the CLL subgroups
stratified according to genetic lesions (del13, del11, del17,
12+ and FISH negative) in a two-class supervised analysis
with the N, MZ and SM group (data not shown). Finally,
in agreement with PCA, supervised analysis confirmed the
strong differences in sno/scaRNA expression between
pBC and CLL samples, showing the up-regulation of 102
sno/scaRNAs and the down-regulation of a single tran-
script (SNORA36C) in CLL patients (Additional file 4).Figure 1 sno/scaRNA expression profile of CLL and normal B-cells. A
three-dimensional space of similarity to SM, N and MZ tonsillar B-lymphocy
and 17 scaRNA genes (A). Heatmap of the differentially expressed sno/scaR
resulting from two-class supervised analysis comparing CLL and N-SM-MZGlobal sno/scaRNA expression profiling in CLL patients
To determine whether the natural grouping of global sno/
scaRNA expression profiling could be associated with par-
ticular CLL subgroups, we performed an unsupervised
analysis using conventional hierarchical agglomerative
clustering of 71 snoRNAs and 9 scaRNAs, the average
change of which varied at least 1.5-fold in the expression
levels from the mean values across the dataset (Additional
file 5 and Additional file 6). However, CLL samples
appeared scattered along the dendrogram irrespective of
any known molecular characteristic.
Consequently, we performed supervised analyses (q
value = 0) to investigate the occurrence of specific sno/
scaRNA expression patterns in CLL groups stratified
according to the presence/absence of different prognostic
markers; i.e. IGHV gene mutations and ZAP-70 and CD38
expression. Significant differences were detected only in
the expression of a limited number of transcripts in the
groups stratified as above (Table 2). Specifically, UM-CLLs
showed the down-regulation of SNORA70F and SNO-
RA70C, and the up-regulation of SNORA71C. Of note,
SNORA70F also was found down-regulated in ZAP-70
positive and in CD38 positive CLL patients, in whom
SNORA70C was also down-regulated. Furthermore,PCA analysis that includes CLL samples shows that CLLs are closer in a
tes than to other B-cell types, based on the expression of 215 snoRNA
NAs in CLL patients, N-SM-MZ B-cells, and GC B-cells. snoRNAs also
B-cells group, are marked with an asterisk (B).
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according to the presence of chromosomal alterations
such as 12+, del11, del13, and del17 by supervised
analyses (at q value = 0). SNORA70F was significantly
down-regulated in CLL patients with 12+ or del11
(Table 2). Overall, lower expression levels of SNO-
RA70F were associated with the cumulative adverse bio-
logical and molecular features (see Additional file 7).
Moreover, 12+ patients displayed the significant down-
regulation of SCARNA17 and up-regulation of three
snoRNAs located on chromosome 12 (SNORA2B,
SNORD59A, and -59B) (Table 2). The significant down-Table 2 Supervised analysis comparing CLLs with adverse vs
NEGATIVE PROGNOSTIC FACTOR sno/scaRNA Alias
IGHV unmutated SNORA70F U70F
SNORA70C U70C
SNORA71C U71C
ZAP70 pos SNORA70F U70F




























Abbreviations: scaRNA small Cajal body-specific RNA, snoRNA small nucleolar RNA.regulation of SCARNA9 which is located at 11q21
(Table 2), was also observed in cases with del11. Inter-
estingly, in 8/13 del11 cases, for which genome-wide
data were available, we observed that the SCARNA9
locus was included in the deleted region (data not
shown). By comparing patients with/without del13 we
identified 17 snoRNAs and 2 scaRNAs consistently
down-regulated in del13 samples (Table 2). Finally, su-
pervised analysis of CLL samples with del17 did not
show any differentially expressed sno/scaRNAs, a find-
ing that could be, however, related to the low number
of cases.favorable prognostic factors
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of their corresponding host genes
The vast majority of human sno/scaRNAs are encoded
sense-oriented in introns of so-called host genes, and
are produced by exonucleolytic processing of the
debranched intron after splicing. This suggests that sno/
scaRNAs and their host genes may have a coordinate ex-
pression. Among 169 sno/scaRNA-host gene couples
present on Human Gene 1.0 ST array, we identified by
means of the non parametric Kendall τ correlation test,
75 snoRNAs and 4 scaRNAs whose expression levels
were significantly correlated with those of their corre-
sponding host genes (Additional file 8); this list includes
15 sno/scaRNAs resulting from the supervised analyses
carried out in our study (Table 3). Specifically,
SNORA2B and the SNORD59A, -59B cluster, all of
which located at 12q13, were up-regulated in patients
with 12+ together with their corresponding host tran-
scripts c12orf41 and ATP5B (mitochondrial ATP syn-
thase). Similarly, the expression of SNORA31, which is
located at 13q14, was correlated with that of the host
gene TPT1. Notably, the expression of SNORA70F was
significantly associated with that of its host gene
COBLL1, whereas the expression of the SNORA6 and
−62 cluster was significantly correlated with that of its
host gene RPSA.
Identification of sno/scaRNA transcriptional profile with
clinical relevance in the definition of high-risk CLLs
The sno/scaRNAs transcriptional profiles were examined
in relation to CLL clinical course in 191/211 CLL patients
for whom clinical follow-up was almost 6 months. In par-
ticular, we evaluated whether a specific sno/scaRNA signa-
ture was significantly associated with PFS in our
prospective series. To this aim, we determined possible as-
sociations between PFS and each of the 80 most variable
sno/scaRNAs across the CLL dataset (i.e. sno/scaRNAs
whose average ratio of the expression was at least 1.5 folds
above the mean values). Of these 80 sno/scaRNAs, 5
showed significant association with PFS (P < .05, see Add-
itional file 5), i.e. SNORD116-18, SNORA70F, SNORA74A,
SNORD56, and SNORD1A.
As a further validation, the expression levels of
SNORD1A, and SNORA74A were evaluated in 50 sam-
ples by quantitative real time PCR (qRT-PCR) as previ-
ously described [19]: the linear correlation analysis
indicated a good correspondence between the two tech-
niques (Pearson’s correlation coefficient of 0.71 and 0.76,
respectively; data not shown).
Therefore, we focused on each of the 5 snoRNAs as
unique predictive factor. Based on the K-means clustering
stratification of CLL cases into two groups according to
snoRNAs expression level, we found that each snoRNA
resulted capable of providing significant predictive valuerelated to PFS in the univariate log-rank test (P < .05,
Table 4). However, in multivariate analysis, only
SNORA74A, SNORD116-18 and SNORD56 retained their
independence (Additional file 9). Specifically, high expres-
sion of SNORA74A and SNORD116-18, and low expres-
sion of SNORD56 were associated with shorter PFS. We
therefore focused on SNORA74A and SNORD116-18,
whose ratio between median high- and low-expression
levels exceeded two-fold (Additional file 3), to evaluate
whether their combination could improve the robustness
of the single-snoRNA model, based on the scheme of
three groups defined by (i) high/high, (ii) low/low or (iii)
discordant expression levels. Significantly, better PFS was
identified in patients with the concomitant low expression
of SNORA74A and SNORD116-18, whereas no difference
emerged between the two other groups, namely those in-
cluding patients with high expression of both or one of
the two snoRNAs (data not shown). Based on these find-
ings, we could define a low-risk group that included 110
patients (58%) characterized by the low expression of both
snoRNAs, and a high-risk group (81 patients) character-
ized by the high expression of at least one of the two
snoRNAs. The high-risk group had a hazard ratio of 2.53
(95% CI: 1.48-4.32) and a median PFS of 39 months
(Table 5 and Figure 2), versus a median PFS not reached
in low-risk group. The robustness of the 2-snoRNA model
was tested by leave-one-out cross validation procedure,
which ultimately led to near 90% accuracy.
Multivariate Cox regression analysis was finally
performed to test the independence of the 2-snoRNAs
risk model from known predictive factors in CLL (IGHV
mutational status, ZAP-70 and CD38 expression and un-
favorable chromosomal aberration) as covariates. The
analysis ascertained the independent prognostic value of
the 2-snoRNAs model in our series (p = 0.0007, Table 5).
Discussion
The relevance of non-coding RNA sequences in human
disease has increased remarkably over the past years.
miRNAs represent the most extensively investigated cat-
egory of ncRNAs in cancer since there are genetic and
epigenetic defects causing their deregulation and con-
tributing to tumorigenesis. However, other ncRNAs,
such as PIWI-interacting RNAs (piRNAs), small nucle-
olar RNAs (snoRNAs), transcribed ultraconserved re-
gions (T-UCRs) and large intergenic non-coding RNAs
(lincRNAs) are emerging as key elements of cellular
homeostasis. The deregulation of these RNAs may con-
tribute to the development of many different human dis-
orders, including cancer [14].
snoRNAs and scaRNAs play important roles in the mat-
uration of rRNA, tRNA, snRNA as well as in mRNA bio-
genesis [34]. sno/scaRNAs may also be involved in human
cancers as demonstrated by recent studies in MM,
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scribe for the first time the global expression profiles of
sno/scaRNAs in the cells from a large cohort of CLL
cases already characterized for many features. These
profiles were also compared with those of various sub-
populations of normal B-cells from peripheral blood
and from tonsils.Table 3 Correlation of expression levels of sno/scaRNAs resul
corresponding host-genes
Sno/scaRNA Alias Cytoband Host gene
SNORD45B U45B 1p31.1 RABGGTB
SNORD38A U38A 1p34 RPS8
SNORD38B U38B 1p34 RPS8
SNORA16A ACA16 1p35.3 SNHG12
SNORD76 U76 1q25 GAS5
SNORD94 U94 2p11.2 PTCD3
SNORA70F U70F 2q24 COBLL1
SNORA6 ACA6 3p22 RPSA
SNORA62 E2 3p22 RPSA
SCARNA7 U90 3q25 KPNA4
SNORA24 ACA24 4q26 SNHG8
SNORD50A U50 6q14 SNHG5
SNORA20 ACA20 6q25 TCP1
SNORD54 U54 8q12.1 RPS20
SNORA70C U70C 9q33.1 ASTN2
SNORD15B U15B 11q13.4 RPS3
SCARNA9 mgU2-19/30 11q21 KIAA1731
SCARNA10 U85 12p13 NCAPD2
SNORA2B ACA2B 12q13.11 C12orf41
SNORD59B U59B 12q13.3 ATP5B
SNORD59A U59 12q13.3 ATP5B
SNORA70G U70G 12q15 RAB1B
SNORA31 ACA31 13q14.13 TPT1
SNORD8 mgU6-53 14q11 CHD8
SNORD116-23 HBII-85-23 15q11.2 SNRPN
SNORD116-1 HBII-85-1 15q11.2 SNRPN
SNORD116-29 HBII-85-29 15q11.2 SNRPN
SNORD60 U60 16p13 LOC10050730
SNORD104 U104 17q23 ORGUL028719
SCARNA17 mgU12-22/U4-8 18q21.1 Ib
SNORA68 U68 19p13 RPL18A
SNORD37 U37 19p13.3 EEF2
SNORD34 U34 19q13 RPL13A
SNORA71C U71C 20q11.23 LOC388796
SNORA36A ACA36 Xq28 DKC1
Abbreviations: scaRNA small Cajal body-specific RNA, snoRNA small nucleolar RNA. ap
transcriptional unit; snoRNA significantly correlating with corresponding host geneThe identification of the normal B-cell counterpart of
CLL (namely SM and MZ B-cells on one side and N B-
cells on the other) is currently a debated question [35,36].
Although based on a limited number of normal samples,
our analysis revealed that the sno/scaRNA expression pro-
file of leukemic cells is much more similar to N, MZ and
M B-cells than to GC or total pB- cells. Therefore, sno/ting from multiclass or supervised analyses and
Kendall q-value Target RNA
7.260E-14 18S rRNA A159 and 18S rRNA U172
Aa 28S rRNA A1858
Aa 28S rRNA A1858
2.540E-02 28S rRNA U4412
Aa 28S rRNA A2350
5.609E-01 U6 snRNA C62
<2.2e-16 18S rRNA U1692
4.180E-06 28S rRNA U3616
6.380E-06 28S rRNA U3830 and 28S rRNA U3832
8.912E-01 U1 snRNA A70
Aa 18S rRNA U863 and 18S rRNA U609
Aa 28S rRNA C2848 and 28S rRNA G2863
1.000E+00 18S rRNA U651
<2.2e-16 18S rRNA G644
3.760E-06 18S rRNA U1692
<2.2e-16 28S rRNA A3764
1.050E-01 U2 snRNA G19 and U2 snRNA A30
3.746E-01 U5 snRNA U46 and U5 snRNA C45
<2.2e-16 28S rRNA U4263 and 28S rRNA U4282
3.530E-07 18S rRNA A1031
9.032E-04 18S rRNA A1031
1.000E+00 18S rRNA U1692
2.951E-02 18S rRNA U218 and 28S rRNA U3713




3 Aa 28S rRNA G4340
Aa 28S rRNA C1327
U4 snRNA C8 and U12 snRNA G22
Aa 28S rRNA U4393
1.845E-03 28S rRNA A3697
Aa 28S rRNA U2824
1.910E-01 18S rRNA U406
1.561E-03 18S rRNA U1244 and 18S rRNA U105
robe not present onto Human Gene 1.0 ST arrays; bIndependent
is typed in bold.
Figure 2 PFS of patients grouped according to the snoRNAs-
based model. Kaplan-Meier curves of the 2 groups defined by the
2-snoRNAs model identifying a low-risk group characterized by the
low expression of both snoRNAs and a high risk group characterized
by the high expression of at least one of the two snoRNAs. The high
risk group has a median PFS of 39 months.
Table 4 SnoRNAs with significant predictive value related
to PFS in the univariate log-rank test
Variable HR Lo 95% CI Up 95% CI p-val
SNORD1A 0.47 0.27 0.82 6.03 E-03
SNORD56 0.5 0.3 0.83 6.08 E-03
SNORA70F 0.4 0.24 0.66 2.41 E-04
SNORD116-18 2.49 1.46 4.27 5.64 E-04
SNORA74A 2.37 1.4 4 9.27 E-04
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cells and N, MZ and SM B-cells, might be of relevance
in disease pathogenesis. These are SNORA31, -6, -62,
and 71C, all of them representing canonical “H/ACA
snoRNAs”, which bind to conserved core box H/ACA
snoRNP proteins, such as DKC1, GAR1, NHP2 and
NOP10, and act mainly as guide RNAs for the site-
specific pseudouridylation of specific target rRNA [15].
Notably, all of these ncRNAs were down-regulated in
CLL cells (Figure 1B) irrespective of the presence or ab-
sence of other genetic lesions (data not shown). Specif-
ically, SNORA31 was significantly down-regulated in
association with its host gene TPT1 (Table 3), which en-
codes for a critical protein involved in the control of
stemness, pluripotency, or tumor reversion [37]. In
addition, TPT1 mRNA is capable of activating the
dsRNA-dependent protein kinase PKR, which is in turn
critical for the tumor suppressor function of TP53 [37].
At present it is unknown whether SNORA31 down-
regulation may have a pathological role per se, or
whether this down-regulation merely represents a
marker of TPT1 down-regulation. SNORA6 and −62,
were both down-regulated in association with their
common host gene RPSA (Table 3). This gene encodes
for a protein that, depending on its folding configur-
ation, may have different cellular activities in specific
compartments, that is the ribosomal protein SA or
the laminin membrane receptor. Cytometric studies
reported that the immature laminin receptor which, un-
like the mature receptor, is not acylated, is specifically
expressed on the surface of CLL B-cells but not in N,Table 5 Multivariate analysis comparing the 2-snoRNAs
risk model with prognostic variables in CLLs series
Variable HR Lo 95% CI Up 95% CI p-val
2-snoRNAs MODEL 2.53 1.48 4.32 0.0007
UM-CLL 1.86 0.92 3.79 0.0854
ZAP-70 1.27 0.69 2.36 0.4411
CD38 2.61 1.43 4.77 0.0018
del11 1.76 0.81 3.83 0.1518
del17 1.41 0.32 6.31 0.6494
12+ 1.05 0.52 2.15 0.8867GC, or SM B-lymphocytes from normal tonsils. Moreover,
its expression correlated with mutated IGHV status
predicting a favorable prognosis in CLL [38]. These data
are in apparent conflict with ours, although it is possible
that down-regulation of the RPSA gene does not affect the
translated gene fraction folded as immature laminin recep-
tor, but rather the co-regulated expression of SNORA6
and −62. Finally, CLL cells significantly down-regulated
SNORA71C located in a cluster at chromosome 20q11 in-
cluding SNORA71A, -71B, and -71D.
Our data based on unsupervised analyses suggest an
heterogeneous pattern of sno/scaRNA expression profiles
within the major CLL subgroups classified according to
biological, molecular and cytogenetic markers. This is dif-
ferent from the evidence in MM showing specific sno/
scaRNA expression patterns associated with distinct mo-
lecular subgroups of the disease [19]. However, supervised
analyses demonstrated specific, albeit limited, signatures
of sno/scaRNA expression in distinct molecular and gen-
etic CLL groups (Table 2). To note, SNORA70F was found
consistently down-regulated in patients associated with
adverse prognostic markers, such as unmutated IGHV,
ZAP70 and CD38 positivity, 12+, and del11. SNORA70F
is located within the first intron of the COBLL1 gene, the
expression of which correlates significantly with that of
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regulated in UM-CLLs [39] as well as in CLL with a poor
prognosis in general [40]. The exact function of the
COBLL1-encoded protein is still unknown, although data
have suggested an involvement in mid-brain neural tube
closure [41]. Moreover, COBLL1 is a negative regulator of
apoptosis in malignant mesothelioma cells and its expres-
sion is associated with a relatively better prognosis [42].
Finally, we provided evidence that patients with del11 or
12+ deregulated sno/scaRNAs located in the respective al-
tered chromosome; in particular, 12+ samples exhibited a
significant up-regulation of snoRNAs host genes as well
(Table 2), supporting the notion that the gene dosage ef-
fects brought about by this lesion may have a pathogenetic
value [43].
With regards to the potential clinical relevance of this
specific ncRNA family in cancer, recent reports indicated
the association of SNORD25, SNORD27, SNORD30, and
SNORD31 with progression from smoldering to symp-
tomatic MM [18] and the over-expression of SNORD71 in
peripheral T-cell Lymphoma with favorable outcome [22].
In our study, we generated a 2-snoRNAs risk model which
appears to be able to distinguish two different prognostic
groups in our series of Binet stage A CLL patients, inde-
pendently of all the other known molecular markers. Spe-
cifically, the high-risk group was characterized by the
high expression of at least one of the two snoRNAs,
SNORA74A and SNORD116-18.
Little is known about SNORA74A, which is found to
be processed from the second intron of a long pre-
mRNA-like transcript, termed precursor U19H RNA. At
least five transcripts are obtained by alternative splicing
of the long U19H gene, and only one form (approxi-
mately 2%) encodes for a protein, MATR3, involved in
mRNA stabilization [44,45]. This evidence may explain
why SNORA74A expression does not correlate with that
of MATR3, a phenomenon also observed in MM pa-
tients [19]. SNORD116-18 belongs to a cluster of 29
highly similar copies that, together with the SNORD115
cluster, are tandemly-arranged within the introns of the
SNURF–SNRPN transcript, which contains at least 148
exons spanning more than 460 kb on chromosome 15q11.
This genomic region is known to be affected by minimal
deletions associated with the Prader–Willi syndrome
(PWS) [46]. The expression of SNURF–SNRPN, as well as
that of other several genes in this region, is finely regulated
by a bipartite imprinting center (IC) which silences most
maternal genes of the PWS critical region allowing the
SNURF–SNRPN pre-mRNA to be expressed only from
the paternal allele. However, mechanisms other than IC
methylation may contribute to the deregulated expression
of SNORD116 in MM [19]. To note, SNORD116-18 be-
longs to a subgroup of so-called “orphan” sno/scaRNAs
which lack apparent complementarities to cellular RNAs.These molecules may play a role in the regulation of alter-
native splicing mRNAs, as demonstrated for murine
SNORD115 which is processed to a shorter form binding
to complementary target sequences on the HTR2C pre-
mRNA for the correct alternative splicing of the serotonin
receptor mRNA [47]. A role in the 3′ processing of se-
lected snoRNAs has also been proposed for SCARNA22
which is deregulated in MM in association with its host
gene MMSET, involved in the t(4,14) chromosomal trans-
location [17]. A similar function could be suggested for
SNORD116 variants, as also predicted by the recent avail-
able snoTARGET open source [48]. In this perspective, it
is conceivable that SNORD116-18 deregulation might also
have a role in CLL cell since the involvement of uncor-
rected splicing mechanisms in CLL pathology is supported
by increasing evidence [40,49]. Unfortunately, the lack of
either independent publicly available datasets or some
standardizable methodology prevented the identified 2-
snoRNA model from being considered a pure classifier;
however, our results provided important indication on the
possible role of non-coding RNA in the prognosis of CLL,
and prompt for further investigations.
Conclusions
In conclusion, our data extend the current view of ncRNA
deregulation in cancer pointing to the potential relevance
of the sno/scaRNA family in the context of CLL which
may contribute to discover novel putative molecular
markers associated with the disease.Additional files
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